PALIPERIDONE PALMITATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Paliperidone Palmitate, and when can generic versions of Paliperidone Palmitate launch?
Paliperidone Palmitate is a drug marketed by Teva Pharms Usa and is included in one NDA.
The generic ingredient in PALIPERIDONE PALMITATE is paliperidone palmitate. There are thirty-eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the paliperidone palmitate profile page.
Recent Clinical Trials for PALIPERIDONE PALMITATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Janssen-Cilag International NV | Phase 4 |
| Alliance for Clinical Trials in Oncology | Phase 1 |
Medical Subject Heading (MeSH) Categories for PALIPERIDONE PALMITATE
Anatomical Therapeutic Chemical (ATC) Classes for PALIPERIDONE PALMITATE
Paragraph IV (Patent) Challenges for PALIPERIDONE PALMITATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| INVEGA TRINZA | Extended-release Injectable Suspension | paliperidone palmitate | 273 mg/0.875 mL and 410 mg/1.315 mL | 207946 | 1 | 2021-07-14 |
| INVEGA TRINZA | Extended-release Injectable Suspension | paliperidone palmitate | 819 mg/2.625 mL | 207946 | 1 | 2021-04-30 |
| INVEGA TRINZA | Extended-release Injectable Suspension | paliperidone palmitate | 546 mg/1.75 mL | 207946 | 1 | 2020-06-24 |
| INVEGA SUSTENNA | Extended-release Injectable Suspension | paliperidone palmitate | 39 mg/0.25 mL, 78 mg/0.5 mL, 117 mg/0.75 mL, 156 mg/mL and 234 mg/1.5 mL | 022264 | 1 | 2017-11-21 |
US Patents and Regulatory Information for PALIPERIDONE PALMITATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | PALIPERIDONE PALMITATE | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 211149-001 | Jul 6, 2021 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Teva Pharms Usa | PALIPERIDONE PALMITATE | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 211149-004 | Jul 6, 2021 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Teva Pharms Usa | PALIPERIDONE PALMITATE | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 211149-002 | Jul 6, 2021 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Teva Pharms Usa | PALIPERIDONE PALMITATE | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 211149-003 | Jul 6, 2021 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Teva Pharms Usa | PALIPERIDONE PALMITATE | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 211149-005 | Jul 6, 2021 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
